Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan
Translational and Regulatory Sciences · 2026 · 8 (2) · 7-14
DOI: 10.33611/trs.2026-002 ↗Kurz gefasst
Leitlinie in der Zeitschrift Translational and Regulatory Sciences, 2026. Verfasst von Takuya NISHIMURA und 9 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
NISHIMURA, T., OKUBO, Y., NAOTA, M., SUZUKI, Y., SUZUKI, M., WATANABE, K., NAKAZAWA, T., KUWAGATA, M., ONODERA, H., & HIRABAYASHI, Y. (2026). Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan. Translational and Regulatory Sciences, 8(2), 7-14. https://doi.org/10.33611/trs.2026-002
Vancouver
NISHIMURA T, OKUBO Y, NAOTA M, SUZUKI Y, SUZUKI M, WATANABE K, et al. Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan. Translational and Regulatory Sciences. 2026;8(2):7-14. doi:10.33611/trs.2026-002
BibTeX
@article{NISHIMURA2026,
author = {NISHIMURA, Takuya and OKUBO, Yusuke and NAOTA, Misaki and SUZUKI, Yui and SUZUKI, Mutsumi and WATANABE, Kazuto and NAKAZAWA, Takahiro and KUWAGATA, Makiko and ONODERA, Hiroshi and HIRABAYASHI, Yoko},
title = {Challenges in the nonclinical safety evaluation of biotechnology-derived pharmaceuticals and perspectives for revision of the ICH S6 guideline based on analysis of approved products in Japan},
journal = {Translational and Regulatory Sciences},
year = {2026},
volume = {8},
number = {2},
pages = {7--14},
doi = {10.33611/trs.2026-002}
}
EUVIMED